These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 30442276)

  • 101. Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China.
    Pei W; Yue S; Zhi-Hao Y; Ruo-Yu Z; Bin W; Nan L
    Eur J Health Econ; 2021 Sep; 22(7):1083-1093. PubMed ID: 33893889
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Quality Control Process for EQ-5D-5L Valuation Studies.
    Ramos-Goñi JM; Oppe M; Slaap B; Busschbach JJ; Stolk E
    Value Health; 2017 Mar; 20(3):466-473. PubMed ID: 28292492
    [TBL] [Abstract][Full Text] [Related]  

  • 103. General population normative data for the EQ-5D-3L in the five largest European economies.
    Janssen MF; Pickard AS; Shaw JW
    Eur J Health Econ; 2021 Dec; 22(9):1467-1475. PubMed ID: 34117986
    [TBL] [Abstract][Full Text] [Related]  

  • 104. An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies.
    Shah K; Mulhern B; Longworth L; Janssen MF
    Value Health; 2016 Jan; 19(1):53-9. PubMed ID: 26797236
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Testing 2 Alternative Time Trade-Off Methods for Valuation of Children's Health States.
    Yang Z; Devlin NJ; Rand K; Luo N
    Value Health; 2024 Jan; 27(1):43-50. PubMed ID: 37813195
    [TBL] [Abstract][Full Text] [Related]  

  • 106. General population reference values for 3-level EQ-5D (EQ-5D-3L) questionnaire in Poland.
    Golicki D; Niewada M
    Pol Arch Med Wewn; 2015; 125(1-2):18-26. PubMed ID: 25578383
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Scuffham PA
    Health Qual Life Outcomes; 2013 Sep; 11():149. PubMed ID: 24070162
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Population health status based on the EQ-5D-Y-3L among adolescents in Sweden: Results by sociodemographic factors and self-reported comorbidity.
    Åström M; Persson C; Lindén-Boström M; Rolfson O; Burström K
    Qual Life Res; 2018 Nov; 27(11):2859-2871. PubMed ID: 30196340
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study.
    Ryan JM; McKay E; Anokye N; Noorkoiv M; Theis N; Lavelle G
    BMJ Open; 2020 Sep; 10(9):e037089. PubMed ID: 32912983
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Does Inclusion of Interactions Result in Higher Precision of Estimated Health State Values?
    Nicolet A; Groothuis-Oudshoorn CGM; Krabbe PFM
    Value Health; 2018 Dec; 21(12):1437-1444. PubMed ID: 30502788
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Comparing and transforming PROMIS utility values to the EQ-5D.
    Hartman JD; Craig BM
    Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong.
    Wong ELY; Ramos-Goñi JM; Cheung AWL; Wong AYK; Rivero-Arias O
    Patient; 2018 Apr; 11(2):235-247. PubMed ID: 29019161
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Normative Values and Psychometric Properties of EQ-5D-Y-3L in Chilean Youth Population among Different Weight Statuses.
    Perez-Sousa MA; Olivares PR; Carrasco-Zahinos R; Garcia-Hermoso A
    Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36901107
    [TBL] [Abstract][Full Text] [Related]  

  • 115. An experience- and preference-based EQ-5D-3L value set derived using 18 months of longitudinal data in patients who sustained a fracture: results from the ICUROS.
    Svedbom A; Borgstöm F; Hernlund E; Alekna V; Bianchi ML; Clark P; Diaz-Curiel M; Dimai HP; Jürisson M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA
    Qual Life Res; 2023 Apr; 32(4):1199-1208. PubMed ID: 36495384
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Valuing health-related quality of life: An EQ-5D-5L value set for England.
    Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
    Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
    Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
    Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
    Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
    Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst Scaling.
    Dalziel K; Catchpool M; García-Lorenzo B; Gorostiza I; Norman R; Rivero-Arias O
    Pharmacoeconomics; 2020 May; 38(5):499-513. PubMed ID: 31974830
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
    Whitehurst DG; Norman R; Brazier JE; Viney R
    Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.